This Article Free upon publication Full Text Full Text (PDF) All Versions of this Article: 112/4/498    most recent CIRCULATIONAHA.104.522706v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnsen, S. H. Articles by Arnesen, E. Search for Related Content PubMed PubMed Citation Articles by Johnsen, S. H. Articles by Arnesen, E. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Carotid Artery Disease Related Collections Risk Factors Imaging Carotid Stenosis Doppler ultrasound, Transcranial Doppler etc. Epidemiology Lipid and lipoprotein metabolism

(Circulation. 2005;112:498-504.)
© 2005 American Heart Association, Inc.

Epidemiology

Elevated High-Density Lipoprotein Cholesterol Levels Are Protective Against Plaque Progression

A Follow-Up Study of 1952 Persons With Carotid Atherosclerosis The Tromsø Study

Stein Harald Johnsen, MD; Ellisiv B. Mathiesen, MD, PhD; Einar Fosse, MD; Oddmund Joakimsen, MD, PhD; Eva Stensland-Bugge, MD, PhD; Inger Njølstad, MD, PhD; Egil Arnesen, MD

From the Institute of Community Medicine (S.H.J., E.B.M., E.F., I.N., E.A.), University of Tromsø, and Department of Neurology (E.B.M., O.J., E.S.-B.), University Hospital of Northern Norway, Tromsø, Norway.

Correspondence to Stein Harald Johnsen, Institute of Community Medicine, University of Tromsø, N-9037 Tromsø, Norway. E-mail Stein.Johnsen{at}ism.uit.no

Received December 1, 2004; revision received March 22, 2005; accepted April 11, 2005.

Background— There is an inverse relationship between HDL cholesterol and coronary heart disease. Experimental studies have indicated that HDL cholesterol may exert an antiatherogenic effect by inducing regression of atherosclerotic plaques and by turning lipid-rich plaques into more fibrotic lesions. In this prospective, population-based ultrasound study, we investigated how HDL cholesterol relates to carotid plaque progression.

Methods and Results— The study included 1952 men and women aged 25 to 82 years who had at least 1 plaque present in the right carotid artery at baseline examination (1994). All plaque images were computer processed to yield a measure of plaque area in square millimeters and echogenicity, expressed as the gray-scale median. After 7 years of follow-up, a new ultrasound screening was performed, and the changes in plaque area and echogenicity were assessed. In a multivariable adjusted model, HDL cholesterol, age, systolic blood pressure, and current smoking were independent predictors of plaque growth. For a 1-SD (0.41 mmol/L) lower HDL cholesterol level, mean (SE) plaque area increased by 0.93 mm² (0.44 mm²; P=0.03). When users of lipid-lowering drugs were excluded from analysis, the HDL estimate was strengthened (ß=1.46 mm², P=0.002). Although plaque area increased in 70% of cases, and most plaques became more echogenic over the follow-up interval, the plaques that became more echolucent grew more in size than those that became more echogenic (P=0.002).

Conclusions— This study shows that a high level of HDL cholesterol reduces plaque growth in subjects with preexisting carotid atherosclerosis. Transformation of the plaque mass into higher echogenicity is associated with reduced growth. Our findings may indicate that HDL cholesterol stabilizes plaques and counteracts their growth by reducing their lipid content and inflammation.

Key Words: cholesterol, HDL • plaque, carotid • atherosclerosis • carotid arteries • ultrasonics

This article has been cited by other articles:

				R. Bitzur, H. Cohen, Y. Kamari, A. Shaish, and D. Harats Triglycerides and HDL Cholesterol: Stars or second leads in diabetes? Diabetes Care, November 1, 2009; 32(suppl_2): S373 - S377. [Full Text] [PDF]

				N. Sanossian, J. L. Saver, M. Navab, and B. Ovbiagele High-Density Lipoprotein Cholesterol: An Emerging Target for Stroke Treatment Stroke, March 1, 2007; 38(3): 1104 - 1109. [Abstract] [Full Text] [PDF]

				D. Tschoepe and B. Stratmann Plaque stability and plaque regression: new insights Eur. Heart J. Suppl., October 1, 2006; 8(suppl_F): F34 - F39. [Abstract] [Full Text] [PDF]

				T. R Pedersen, G. Assmann, J.-P. Bassand, M J. Chapman, R. Erbel, and C. Sirtori Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment Diabetes and Vascular Disease Research, September 1, 2006; 3(2_suppl): S1 - S12. [Abstract] [PDF]

				P. C.N. Rensen and L. M. Havekes Cholesteryl Ester Transfer Protein Inhibition: Effect on Reverse Cholesterol Transport? Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 681 - 684. [Full Text] [PDF]

				J. Ou, J. Wang, H. Xu, Z. Ou, M. G. Sorci-Thomas, D. W. Jones, P. Signorino, J. C. Densmore, S. Kaul, K. T. Oldham, et al. Effects of D-4F on Vasodilation and Vessel Wall Thickness in Hypercholesterolemic LDL Receptor-Null and LDL Receptor/Apolipoprotein A-I Double-Knockout Mice on Western Diet Circ. Res., November 25, 2005; 97(11): 1190 - 1197. [Abstract] [Full Text] [PDF]